Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04775745 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
A Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, sponsored by Newave Pharmaceutical.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT04775745 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma that is actively recruiting participants, run by Newave Pharmaceutical. The registered enrollment target is 60 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04775745, a Phase 1 study of Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma, is actively recruiting participants, sponsored by Newave Pharmaceutical.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
Conditions Studied
Interventions
- DRUG LP-168
Study Locations (4)
Ohio
- University of Cincinnati - Cincinnati
- Ohio State University - Columbus
North Carolina
- Duke Univerisity - Durham
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04775745
The ClinicalTrials.gov registry entry for NCT04775745 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (72% lower). The listed sponsor is Newave Pharmaceutical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which LP-168 is the first listed.
NCT04775745 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, North Carolina, Utah.
Frequently Asked Questions
What is clinical trial NCT04775745 about?
NCT04775745 is a clinical study titled "Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.". This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.
What is the current status of trial NCT04775745?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-07-19. Estimated completion is 2027-12-31.
What conditions does trial NCT04775745 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia.
What interventions are being tested in trial NCT04775745?
The interventions under investigation include: LP-168 (DRUG).
Who is sponsoring clinical trial NCT04775745?
This trial is sponsored by Newave Pharmaceutical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04775745 being conducted?
This trial has 4 study locations across North Carolina, Ohio, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Diffuse Large B Cell Lymphoma
All registered trials for this condition
Mantle Cell Lymphoma
All registered trials for this condition
North Carolina
All trials with a study site in North Carolina
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.